Skip to main content
Quest Diagnostics

Alternative Specimen Collection Options

Today’s podcast discussion will focus on the importance of drug monitoring and the benefits of “alternative” sample collection options during the COVID-19 pandemic. Key information shared will include:

  • How clinical drug monitoring is a critical tool to help assess prescription compliance with controlled substances and help identify drug misuse
  • Situations, including the COVID-19 pandemic, when in-office collection isn't always possible
  • Quest Diagnostics’ offerings for alternative specimen collection options, including:
    - Self /At-Home collection
    - Patient Service Center collection
  • How alternative collection options can help ensure your patients get the testing they need

The episode will feature Quest Senior Medical Advisor, Dr Jeff Gudin, and Jason Suomala, Senior Product Manager for the Quest Diagnostics Drug Monitoring and Toxicology division.

Date: Wednesday, April 21, 2021

Author(s): Gudin, J, Suomala, J

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.